OTCPK:LENS.F

Stock Analysis Report

Executive Summary

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Share Price & News

How has Presbia's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

25.0%

LENS.F

1.9%

US Medical Equipment

0.5%

US Market


1 Year Return

-99.0%

LENS.F

15.6%

US Medical Equipment

6.8%

US Market

Return vs Industry: LENS.F underperformed the US Medical Equipment industry which returned 15.6% over the past year.

Return vs Market: LENS.F underperformed the US Market which returned 6.8% over the past year.


Shareholder returns

LENS.FIndustryMarket
7 Day25.0%1.9%0.5%
30 Day-58.3%-2.1%-0.8%
90 Day-84.6%-0.4%-0.9%
1 Year-99.0%-99.0%16.6%15.6%9.2%6.8%
3 Year-99.7%-99.7%72.2%67.0%45.6%36.2%
5 Yearn/a125.9%100.9%63.2%45.4%

Price Volatility Vs. Market

How volatile is Presbia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Presbia undervalued compared to its fair value and its price relative to the market?

0.14x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LENS.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LENS.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LENS.F is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: LENS.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LENS.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LENS.F is good value based on its PB Ratio (0.1x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Presbia forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Presbia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of LENS.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Presbia's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Presbia performed over the past 5 years?

1.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: LENS.F is unprofitable, but has reduced losses over the past 5 years at a rate of 1.7% per year.

Accelerating Growth: Unable to compare LENS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LENS.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: LENS.F has a negative Return on Equity (-545.01%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: LENS.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: LENS.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Presbia's financial position?


Financial Position Analysis

Short Term Liabilities: LENS.F's short term assets ($2.8M) exceeds its short term liabilities ($965.0K)

Long Term Liabilities: LENS.F's short term assets (2.8M) exceeds its long term liabilities (2.0M)


Debt to Equity History and Analysis

Debt Level: LENS.F's debt to equity ratio (125.3%) is considered high

Reducing Debt: LENS.F had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: LENS.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: LENS.F's debt is covered by short term assets (assets are 1.437200x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if LENS.F has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if LENS.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Presbia's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate LENS.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LENS.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if LENS.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LENS.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LENS.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Presbia's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average management tenure


CEO

Zohar Loshitzer (62yo)

0.4yrs

Tenure

0

Mr. Zohar Loshitzer serves as Executive Chairman of the Board and Chief Executive Officer at Presbia PLC since May 01, 2019. Mr. Loshitzer serves as a Principal at Orchard Capital since January 2005. Mr. L ...


CEO Compensation Analysis

Compensation vs. Market: Zohar's total compensation ($USD0.00) is too low to compare against companies of similar size in the US market ($USD503.30K).

Compensation vs Earnings: Zohar's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.2yrs

Average Tenure

65yo

Average Age

Experienced Management: LENS.F's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Age and Tenure

4.2yrs

Average Tenure

61.5yo

Average Age

Experienced Board: LENS.F's board of directors are considered experienced (4.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Zohar Loshitzer (62yo)

    Executive Chairman & CEO

    • Tenure: 0.4yrs
  • Vlad Feingold (70yo)

    Consultant

    • Tenure: 2.8yrs
    • Compensation: US$13.11m
  • Rick Fogarty (68yo)

    Consultant

    • Tenure: 0.7yrs
    • Compensation: US$323.82k
  • Casey Lind (55yo)

    Chief Operating Officer

    • Tenure: 1.7yrs
    • Compensation: US$531.43k

Board Members

  • Robert Cresci (75yo)

    Director

    • Tenure: 4.6yrs
    • Compensation: US$117.50k
  • Kerry Assil

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Richard Ressler (61yo)

    Director

    • Tenure: 4.8yrs
  • Zohar Loshitzer (62yo)

    Executive Chairman & CEO

    • Tenure: 0.4yrs
  • Mark Blumenkranz (68yo)

    Member of Medical Advisory Board

    • Tenure: 4.2yrs
    • Compensation: US$115.96k
  • Ioannis Pallikaris

    Chairman of Medical Advisory Board

    • Tenure: 0yrs
  • Michael Gordon

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Marco Fantozzi

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Gerd Auffarth (54yo)

    Director

    • Tenure: 4.2yrs
    • Compensation: US$135.00k
  • Gerald Farrell (59yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$117.50k

Company Information

Presbia PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Presbia PLC
  • Ticker: LENS.F
  • Exchange: OTCPK
  • Founded: 2014
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$215.370k
  • Shares outstanding: 17.23m
  • Website: https://www.presbia.com

Number of Employees


Location

  • Presbia PLC
  • Sandyford Office Centre
  • Suite 7
  • Dublin
  • 18
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LENS.FOTCPK (Pink Sheets LLC)YesNew Ordinary SharesUSUSDJan 2015

Biography

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for pro ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 00:39
End of Day Share Price2019/10/18 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.